{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:48:39Z","timestamp":1782031719452,"version":"3.54.5"},"reference-count":30,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ijrobp.2025.01.025","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T03:00:05Z","timestamp":1738897205000},"page":"275-284","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiation Therapy in Hormone-Na\u00efve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study"],"prefix":"10.1016","volume":"125","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7765-4473","authenticated-orcid":false,"given":"Jonathan","family":"Tward","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shane","family":"Lloyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Skyler","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Dechet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brock O.","family":"Nei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Maughan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umang","family":"Swami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumati","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristine","family":"Kokeny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neeraj","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2025.01.025_bib0001","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0002","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: Long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0003","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): Survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0004","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0005","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: A randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0006","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0007","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0008","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.urology.2013.06.062","article-title":"Neoadjuvant androgen deprivation therapy leads to immediate impairment of vitality\/hormonal and sexual quality of life: Results of a multicenter prospective study","volume":"82","author":"Gay","year":"2013","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0009","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ijrobp.2017.02.019","article-title":"External beam radiation therapy or brachytherapy with or without short-course neoadjuvant androgen deprivation therapy: Results of a multicenter, prospective study of quality of life","volume":"98","author":"Gay","year":"2017","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Nguyen","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0011","doi-asserted-by":"crossref","first-page":"158","DOI":"10.5530\/ami.2016.2.31","article-title":"Prostate cancer and androgen deprivation therapy: Metabolic, cardiovascular and psychological side effects","volume":"3","author":"Mosca","year":"2016","journal-title":"Acta Medica Int"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0012","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0013","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00345-019-03063-4","article-title":"Clinical perspectives from ongoing trials in oligometastatic or oligorecurrent prostate cancer: An analysis of clinical trials registries","volume":"39","author":"De Bruycker","year":"2021","journal-title":"World J Urol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0014","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: A prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0015","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: The ORIOLE phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0016","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0017","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s12149-015-1044-9","article-title":"A case report of image-based dosimetry of bone metastases with Alpharadin ((223)Ra-dichloride) therapy: Inter-fraction variability of absorbed dose and follow-up","volume":"30","author":"Pacilio","year":"2016","journal-title":"Ann Nucl Med"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0018","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.jclinepi.2010.04.011","article-title":"The patient-reported outcomes measurement information system (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005-2008","volume":"63","author":"Cella","year":"2010","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0019","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1007\/s11136-014-0732-6","article-title":"Setting standards for severity of common symptoms in oncology using the PROMIS item banks and expert judgment","volume":"23","author":"Cella","year":"2014","journal-title":"Qual Life Res"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0020","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.urology.2014.08.044","article-title":"Minimally important difference for the expanded prostate cancer index composite short form","volume":"85","author":"Skolarus","year":"2015","journal-title":"Urology"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0021","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.6_suppl.67","article-title":"Development and validation of a mutivariate model combining cell cycle progression score with CAPRA to predict prostate cancer mortality in a conservatively managed cohort","volume":"31","author":"Brawer","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0022","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.1586","article-title":"Comparison of genomic instability test scores used for predicting PARP activity in ovarian cancer","volume":"38","author":"Timms","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0023","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0024","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.7_suppl.182","article-title":"External beam radiation therapy (EBRT) use and safety with radium-223 dichloride (Ra-223) in patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets) from the ALSYMPCA trial","volume":"33","author":"Finkelstein","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0025","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.6_suppl.10","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence (STOMP): Five-year results of a randomized phase II trial","volume":"38","author":"Ost","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0026","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1200\/JCO.22.00644","article-title":"Long-term outcomes and genetic predictors of response to metastasis-directed therapy versus observation in oligometastatic prostate cancer: Analysis of STOMP and ORIOLE trials","volume":"40","author":"Deek","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0027","doi-asserted-by":"crossref","first-page":"S7","DOI":"10.1016\/j.ijrobp.2024.08.021","article-title":"Outcomes of RAdium-223 and SABR vs. SABR for oligomEtastatic prostate caNcerS \u2013 The RAVENS phase II randomized trial","volume":"120","author":"Tran","year":"2024","journal-title":"Int J Radiat Oncol, Biol, Phys"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib0028","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1002\/bco2.116","article-title":"Mortality in men with castration-resistant prostate cancer-A long-term follow-up of a population-based real-world cohort","volume":"3","author":"Khoshkar","year":"2022","journal-title":"BJUI Compass"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib29","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ijrobp.2021.09.034","article-title":"The Clinical Cell-Cycle Risk (CCR) score Is associated with metastasis after radiation therapy and provides guidance on when to forgo combined androgen deprivation therapy with dose-escalated radiation","volume":"113","author":"Tward","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2025.01.025_bib30","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.clgc.2021.01.003","article-title":"Personalizing localized prostate cancer: validation of a combined clinical cell-cycle risk (CCR) score threshold for prognosticating benefit from multimodality therapy","volume":"19","author":"Tward","year":"2021","journal-title":"Clin Genitourin Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000951?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301625000951?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,21]],"date-time":"2026-06-21T08:31:50Z","timestamp":1782030710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301625000951"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":30,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0360301625000951"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.025","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 2 Trial of Radium223 and Stereotactic Ablative Radiation Therapy in Hormone-Na\u00efve Men with Oligometastatic Prostate Cancer to Bone: The RadSABR Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2025.01.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}